Direction of the Revision of the Pharmaceutical and Medical Device Act and Related Systems - Quality Assurance, Stable Supply, Support for Drug Discovery, Development of Pharmacy Functions, etc.

Other publications by Kochi Hashimoto

2025.03.28
Key Regulatory Considerations for Pharmaceuticals and Medical Devices in Japan
2024.10.16
Lexology Panoramic Next - M&A : Japan Chapter
2024.05.08
mondaq - ESG Comparative Guide : Japan
2024.02.02
Understanding the Basics: Q&A on the Legal Practice on ESG and Sustainability
2024.01.12
International Trends in Business and Human Rights and the Responses of Japanese Companies
2023.10.16
Getting the Deal Through - Market Intelligence M&A : Japan Chapter
2023.06.23
Business and Human Rights in Japan
2023.05.11
The Legal 500 Country Comparative Guides Japan Environmental, Social and Governance
2023.02.28
Impact of the Enactment of the German Act, "Act on Corporate Due Diligence in Supply Chains," on Japanese Companies
2020.12.01
Start-up Investment Agreement – Model Agreement and Commentary Thereon
2019.06.21
Best Practices of Forming Venture Capital Funds - A Commentary on the New Model Contract and the Market-Value Valuation Method
2018.03.19
The Problem of Unknown Land Owners and the Japanese Real Estate Registration System
2016.09.20
Web Commentary on TPP "22　Competitiveness and Business Facilitation"
2016.09.20
Web Commentary on TPP "24 Small and Medium-Sized Enterprises"
2016.08.15
Issues in TPP:Reading Its Reality and Future in the Agreement:TPP:Integrating SMEs into Global Supply Chains

MORE

Other publications about Marketing Regulation

2025.04.01
Direction of the Revision of the Pharmaceutical and Medical Device Act and Related Systems - Quality Assurance, Stable Supply, Support for Drug Discovery, Development of Pharmacy Functions, etc.
2025.03.24
Legal Affairs for Chinese Life Sciences and Healthcare No. 23: Updates on the Amendments of Pharmaceutical Laws and Regulations of China
2024.01.24
Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
2023.11.28
Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
2023.08.24
Thematic-based: Legal Practice in the Healthcare Business
2022.07.04
China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
2022.05.26
Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.03.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 6) - Trial Program for Cross-border E-commerce Retail Import of Drugs in Henan
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)

MORE

Contact us

ページTOPへ